RxDoctor Payments Data

Kenneth Nicley, PA

Physician Assistant · Maynardville, TNNPI 1306252598

Payments from drug & device makers

$2,783in general payments, 2019–2025

Across 164 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$743
  • GSK$259
  • Novo Nordisk$238
  • Pfizer$236
  • Abbott$190
  • Boehringer Ingelheim$150
  • plus $967 from 22 others

What the payments were for

  • Food & beverage$2,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,783 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,258
Medicare patients
82
Services billed
2,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$90,221
OzempicSemaglutide66$84,735
MounjaroTirzepatide63$71,297
Dupixent PenDupilumab13$50,925
EliquisApixaban45$41,785
XareltoRivaroxaban30$24,189
JardianceEmpagliflozin20$20,064
TrulicityDulaglutide19$18,343
RexultiBrexpiprazole12$16,539
JanuviaSitagliptin Phosphate21$16,054
LinzessLinaclotide25$15,829
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,424
Spiriva RespimatTiotropium Bromide25$14,916
Tresiba Flextouch U-200Insulin Degludec12$14,577
Janumet XrSitagliptin Phos/Metformin Hcl25$14,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$259$90,22191 claims
Lilly USA, LLCMounjaro, Trulicity$116$89,64082 claims
Novo NordiskOzempic$238$84,73566 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Trijardy Xr, Combivent Respimat$150$58,67282 claims
PfizerEliquis$236$41,78545 claims
MerckJanuvia, Janumet Xr$15$30,08046 claims
Johnson & JohnsonXarelto$48$24,18930 claims
AstraZenecaBreztri Aerosphere, Farxiga$45$23,71340 claims
AbbVieLinzess, Fetzima$743$21,65538 claims
Otsuka America Pharmaceutical, Inc.Rexulti$118$16,53912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Maynardville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →